Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Net Cash Flow (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Net Cash Flow for 10 consecutive years, with $222.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 749.94% to $222.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $248.0 million, a 851.52% increase, with the full-year FY2025 number at $248.0 million, up 851.52% from a year prior.
  • Net Cash Flow was $222.1 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $25.8 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $368.5 million in Q2 2024 to a low of -$331.3 million in Q3 2024.
  • A 5-year average of -$14.5 million and a median of -$10.3 million in 2022 define the central range for Net Cash Flow.
  • Biggest YoY gain for Net Cash Flow was 2164.18% in 2024; the steepest drop was 1068.89% in 2024.
  • Ultragenyx Pharmaceutical's Net Cash Flow stood at $100.4 million in 2021, then crashed by 358.92% to -$260.1 million in 2022, then soared by 153.59% to $139.4 million in 2023, then crashed by 81.25% to $26.1 million in 2024, then soared by 749.94% to $222.1 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Net Cash Flow are $222.1 million (Q4 2025), $25.8 million (Q3 2025), and $46.6 million (Q2 2025).